Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.

ABSTRACT:

Background

We aimed to evaluate overall survival in US patients with amyotrophic lateral sclerosis (ALS) treated with intravenous (IV) edaravone compared with those not treated with IV edaravone in a real-world setting.

Methods

This exploratory retrospective comparative effectiveness observational analysis included patients with ALS who were enrolled in an administrative claims database from 8 August 2017 to 31 March 2020. Propensity score matching identified IV edaravone-treated patients (cases) and non-edaravone-treated patients (controls) matched for covariates: age, race, geographic region, sex, pre-index disease duration, insurance, history of cardiovascular disease, riluzole prescription, gastrostomy tube placement, artificial nutrition, noninvasive ventilation, and al

SUBMITTER: Brooks BR 

PROVIDER: S-EPMC9358426 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature